These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 30573670)

  • 1. CRISPR/Cas9 searches for a protospacer adjacent motif by lateral diffusion.
    Globyte V; Lee SH; Bae T; Kim JS; Joo C
    EMBO J; 2019 Feb; 38(4):. PubMed ID: 30573670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
    Hu JH; Miller SM; Geurts MH; Tang W; Chen L; Sun N; Zeina CM; Gao X; Rees HA; Lin Z; Liu DR
    Nature; 2018 Apr; 556(7699):57-63. PubMed ID: 29512652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.
    Sternberg SH; Redding S; Jinek M; Greene EC; Doudna JA
    Nature; 2014 Mar; 507(7490):62-7. PubMed ID: 24476820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.
    Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q
    PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered dual selection for directed evolution of SpCas9 PAM specificity.
    Goldberg GW; Spencer JM; Giganti DO; Camellato BR; Agmon N; Ichikawa DM; Boeke JD; Noyes MB
    Nat Commun; 2021 Jan; 12(1):349. PubMed ID: 33441553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bidirectional Degradation of DNA Cleavage Products Catalyzed by CRISPR/Cas9.
    Stephenson AA; Raper AT; Suo Z
    J Am Chem Soc; 2018 Mar; 140(10):3743-3750. PubMed ID: 29461055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SpRY: Engineered CRISPR/Cas9 Harnesses New Genome-Editing Power.
    Zhang D; Zhang B
    Trends Genet; 2020 Aug; 36(8):546-548. PubMed ID: 32456805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal PAM specificity of a highly similar SpCas9 ortholog.
    Chatterjee P; Jakimo N; Jacobson JM
    Sci Adv; 2018 Oct; 4(10):eaau0766. PubMed ID: 30397647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cas9 specifies functional viral targets during CRISPR-Cas adaptation.
    Heler R; Samai P; Modell JW; Weiner C; Goldberg GW; Bikard D; Marraffini LA
    Nature; 2015 Mar; 519(7542):199-202. PubMed ID: 25707807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the mechanisms of PAMless DNA interrogation by SpRY-Cas9.
    Hibshman GN; Bravo JPK; Hooper MM; Dangerfield TL; Zhang H; Finkelstein IJ; Johnson KA; Taylor DW
    Nat Commun; 2024 Apr; 15(1):3663. PubMed ID: 38688943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of the affinities of CRISPR-Cas9 nucleases for cognate protospacer adjacent motif (PAM) sequences.
    Mekler V; Kuznedelov K; Severinov K
    J Biol Chem; 2020 May; 295(19):6509-6517. PubMed ID: 32241913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the efficiency of CRISPR-Cas9-VQR precise genome editing in rice.
    Hu X; Meng X; Liu Q; Li J; Wang K
    Plant Biotechnol J; 2018 Jan; 16(1):292-297. PubMed ID: 28605576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can SpRY recognize any PAM in human cells?
    Ye J; Xi H; Chen Y; Chen Q; Lu X; Lv J; Chen Y; Gu F; Zhao J
    J Zhejiang Univ Sci B; 2022 May; 23(5):382-391. PubMed ID: 35557039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering a
    Teng Y; Wang J; Jiang T; Zou Y; Yan Y
    ACS Synth Biol; 2023 Sep; 12(9):2764-2772. PubMed ID: 37643152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
    Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
    Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.
    Maji B; Gangopadhyay SA; Lee M; Shi M; Wu P; Heler R; Mok B; Lim D; Siriwardena SU; Paul B; Dančík V; Vetere A; Mesleh MF; Marraffini LA; Liu DR; Clemons PA; Wagner BK; Choudhary A
    Cell; 2019 May; 177(4):1067-1079.e19. PubMed ID: 31051099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The post-PAM interaction of RNA-guided spCas9 with DNA dictates its target binding and dissociation.
    Zhang Q; Wen F; Zhang S; Jin J; Bi L; Lu Y; Li M; Xi XG; Huang X; Shen B; Sun B
    Sci Adv; 2019 Nov; 5(11):eaaw9807. PubMed ID: 31763447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis for the Altered PAM Specificities of Engineered CRISPR-Cas9.
    Hirano S; Nishimasu H; Ishitani R; Nureki O
    Mol Cell; 2016 Mar; 61(6):886-94. PubMed ID: 26990991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted gene disruption by CRISPR/xCas9 system in Drosophila melanogaster.
    Ni XY; Zhou ZD; Huang J; Qiao X
    Arch Insect Biochem Physiol; 2020 May; 104(1):e21662. PubMed ID: 32027059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.